HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Court Shoots Down TiO2 Hazard Classification, Opening Door For Future Challenges

Executive Summary

Titanium dioxide stakeholders argued successfully in the Court of Justice of the European Union that TiO2’s hazard classification in 2020 under the CLP was based on shoddy science and a flawed interpretation of EU law. The industry win comes as the European Commission is finalizing a regulation to establish new CLP hazard classes, including for endocrine disruptors.

You may also be interested in...



EFSA Considering New CBD Toxicity Data While Clock-Stop Causes Industry ‘Economic Harm’

The European Food Safety Authority is evaluating new reproductive and developmental toxicity data published since it paused CBD novel food applications last year due to safety concerns, according to food law consultancy, Legal Foods.

Cosmetics Europe Expanding To Meet Historic Challenges: ‘There’s Never Been A Time Like This’

Director-general John Chave discusses regulatory heavy-handedness in the EU, implications for animal testing, declining European investment, and Cosmetics Europe’s message to policymakers going into the 2024 EU elections and beyond.

EU Reg Consultant On CLP Revisions: Take A Breath, Cost It Out, Consider ‘Lobbying And Pushing Back’

Louise Witter of UK-based Chemical Legislation Professionals spoke with HBW Insight ahead of the European Commission’s 19 December adoption of a proposal to revise the CLP by introducing new hazard classes, including for endocrine disruptors.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel